DAC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-02. Numbers and descriptions here follow the published literature rather than marketing material.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
== Early life and education == Sangeeta Bhatia was born in 1968 in Boston, Massachusetts, to parents who emigrated from India. She is an alumna of Lexington High School in Lexington, MA. Her father was an engineer and entrepreneur, and her mother was one of the first women to receive an MBA in India. Bhatia's interest in engineering was sparked during her 10th-grade biology class and a visit with her father to an MIT lab, where she witnessed a demonstration of an ultrasound machine for cancer treatment. She pursued bioengineering at Brown University, where her involvement in a research group studying artificial organs solidified her decision to pursue graduate studies in the field. After graduating with honors in 1990, Bhatia was initially rejected from the MD-PhD program run by the Harvard-MIT Division of Health Sciences and Technology (HST) but was accepted into the Mechanical Engineering Master's program. She was subsequently accepted into the HST MD-PhD program, where she was advised by Mehmet Toner. She received her Ph.D. in 1997 and her M.D. in 1999, followed by postdoctoral training at Massachusetts General Hospital. Bhatia met her husband, Jagesh Shah, as classmates in HST. Shah is currently an executive in the biotechnology industry. They have two daughters.
=== Lean body mass === Studies have found that HGH reduces body fat and increases lean body mass. However, no increase in muscle strength was observed. This may be explained by short-term fluid retention.
Under the Nobel Foundation statutes, Hahn had six months to deliver the Nobel Prize lecture, and until 1 October 1946 to cash the 150,000 Swedish krona cheque. Hahn was repatriated from Farm Hall on 3 January 1946, but it soon became apparent that difficulties obtaining permission to travel from the British government meant that he would be unable to travel to Sweden before December 1946. Accordingly, the Academy of Sciences and the Nobel Foundation obtained an extension from the Swedish government. Hahn attended the year after he was awarded the prize. On 10 December 1946, the anniversary of the death of Alfred Nobel, King Gustav V of Sweden presented him with his Nobel Prize medal and diploma. Hahn gave 10,000 krona of his prize to Strassmann, who refused to use it.
== Examples == Mastocytosis, including mast cell activation syndrome and eosinophilic esophagitis Chronic fatigue syndrome Systemic vasculitis e.g. SLE, PAN Sarcoidosis – a disease that mainly affects the lungs, brain, joints and eyes, found most often in young African-American women. Hypothyroidism – where the thyroid gland produces too little thyroid hormones. Diabetes mellitus – an imbalance in blood glucose (sugar) levels. Fibromyalgia Ehlers-Danlos syndromes - an inherited connective tissue disorder with multiple subcategories Adrenal insufficiency – where the adrenal glands don't produce enough steroid hormones Coeliac disease – an autoimmune disease triggered by gluten consumption, which may involve several organs and cause a variety of symptoms, or be completely asymptomatic. Ulcerative colitis – an inflammatory bowel disease Crohn's disease – an inflammatory bowel disease Hypertension (high blood pressure) Metabolic syndrome AIDS – a disease caused by a virus that cripples the body's immune defenses. Graves' disease – a thyroid disorder, most often in women, which can cause a goiter (swelling in the front part of the neck) and protruding eyes. Systemic lupus erythematosus – a connective tissue disorder involving mainly the skin, joints and kidneys. Rheumatoid arthritis – an inflammatory disease which mainly attacks the joints. But can also affect a person's skin, eyes, lungs and mouth.
Sources: en.wikipedia.org
== University presidents and administrators == John M. Mason (1789), provost of Columbia College and president of Dickinson College Philip Milledoler (1793), fifth president of Rutgers University Nathaniel Fish Moore (1802), eighth President of Columbia University Isaac Ferris (1816), third president of New York University James Hall Mason Knox (1841), 8th president of Lafayette College John Aikman Stewart (1841), businessman, banker, acting president of Princeton University John Howard Van Amringe (1860), mathematician and dean of Columbia College Seth Low (1870), president of Columbia University and mayor of New York City Nicholas Murray Butler (1882), president of Columbia University, chairman of the Carnegie Endowment for International Peace and Nobel Peace Prize winner, founder of Horace Mann School and the College Board Francis Lister Hawks Pott (1883), Episcopal missionary and president of St. John's University, Shanghai 1888–1941 Thomas Fiske (1885), professor of mathematics at Columbia University; acting dean of Barnard College; president of the American Mathematical Society 1902–1904; secretary of the College Board Frank Pierrepont Graves (1890), former president of the University of Washington, University of Wyoming; commissioner of Education of the State of New York 1921–1940 Frank D. Fackenthal (1906), acting president of Columbia University Dixon Ryan Fox (1911), Union College president 1934–1945 Louis L.
This treatment uses vacuum to remove excess fluid and cellular waste that usually prolongs the inflammatory phase of wound healing. Despite a straightforward mechanism of action, the results of negative pressure wound therapy studies have been inconsistent. Research needs to be carried out to optimize the parameters of pressure intensity, treatment intervals, and exact timing to start negative pressure therapy in the course of chronic wound healing. There is low-certainty evidence that negative pressure wound therapy would improve wound healing in diabetic foot ulcers.
== Structure == Bradykinin, sometimes referred to as BK, is a 9–amino acid peptide chain. The amino acid sequence of bradykinin is: Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (RPPGFSPFR). Its empirical formula is therefore C50H73N15O11.
Ownership of the shroud passed from the House of Savoy to the Catholic Church after the death of the former king Umberto II of Italy in 1983. The microscopist and forensic expert Walter McCrone found, based on his examination of samples taken in 1978 from the surface of the shroud using adhesive tape, that the image on the shroud had been painted with a dilute solution of red ochre pigment in a gelatin medium. McCrone also found that the apparent bloodstains were painted with vermilion pigment, also in a gelatin medium. McCrone's findings were disputed by other researchers, and the nature of the image on the shroud continues to be debated. In 1988, radiocarbon dating by three independent laboratories established that the shroud dates back to the Middle Ages, between 1260 and 1390. The nature and history of the shroud have been the subjects of extensive and long-lasting controversies in both the scholarly literature and the popular press. Although the radiocarbon dating of the shroud is accepted as valid by experts, it continues to generate significant public debate. Defenders of the authenticity of the shroud have questioned the radiocarbon results, usually on the basis that the samples tested might have been contaminated or taken from a repair to the original fabric. Such fringe theories, which have been rejected by most experts, include the medieval repair theory, the bio-contamination theories and the carbon monoxide theory. Currently, the Catholic Church neither endorses nor rejects the authenticity of the shroud as a relic of Jesus.
Chicago, Illinois (includes Kenosha, Wisconsin) Clarksville, Tennessee Cincinnati, Ohio Columbia, Missouri Columbus, Ohio Dayton, Ohio Detroit, Michigan Indianapolis, Indiana Las Vegas, Nevada Lexington, Kentucky Louisville, Kentucky Minneapolis–St. Paul, Minnesota Nashville, Tennessee New York – New Jersey (includes Allentown, Pennsylvania) Orlando, Florida Phoenix, Arizona (no locations in Phoenix proper) St. Louis, Missouri Louisville and Columbus also house bulk-manufacturing (grocery-store sales, meat, and bun production) divisions. Company headquarters and the Porcelain Steel Buildings division are in Columbus, Ohio. In the late 20th century, White Castle tried expanding into three new cities, Philadelphia, Kansas City, and Cleveland-Akron. Those restaurants closed within several years. After a several decade hiatus, the company returned to the Kansas City area in 1985 only to leave again in 2001. White Castle entered the Cleveland-Akron area in 1987 and then exited in December 2014.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.